Am­gen tops cost watch­dog's price gougers list based on 'un­sup­port­ed' in­creas­es for En­brel with­out mean­ing­ful da­ta

In a top 10 rank­ing of the most egre­gious price gougers from 2019, Am­gen’s En­brel topped US cost watch­dog ICER’s naughty list with “un­sup­port­ed” markups that added as much as $403 mil­lion to the na­tion’s drug spend dur­ing that time.

Price in­creas­es for some of phar­ma’s most pop­u­lar drugs have long been a fo­cus of con­sumer ire, but the in­dus­try has ar­gued those in­creas­es are rou­tine and meant to cov­er the cost of R&D in­no­va­tion. With­out mean­ing­ful guid­ance at the state or fed­er­al lev­el, ICER looked to con­nect how much a drug had pro­gressed in the clin­ic com­pared with its in­crease in both whole­sale and net price in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER